New study validates importance of mutations in specific gene in AML therapy

Scientists at the University of California, San Francisco have discovered that mutations in a gene called FLT3 could hold the key to treating the most common type of leukemia in humans, acute myeloid leukemia (AML). A new study validates certain activating mutations in the gene as targets for AML therapy. “These mutations are critically important for the survival of leukemia cells that harbor them,” Neil Shah, who led the research, said. “Our results also identify...